364333-82-4

Basic information

• Product Name: 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)-
• CAS NO: 364333-82-4
• Molecular Formula: C15H13N5O2S
• Molecular Weight: 327.367
• Mol File: 364333-82-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)-(364333-82-4)
• EPA Substance Registry System: 2-Pyrimidinamine, 4-(2,4-dimethyl-5-thiazolyl)-N-(3-nitrophenyl)-(364333-82-4)

Safety Data

• Hazardous Substances Data: 364333-82-4(Hazardous Substances Data)

Upstream product

• 142992-99-2 N-(3-nitro-phenyl)-guanidine nitrate 
• 38205-60-6 5-acetyl-2,4-dimethylthiazole 
• 99-09-2 3-nitro-aniline 

Relevant articles and documents

2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity

Following the identification through virtual screening of 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analogue program was initiated. The first aims were to optimize potency and to evaluate the cellular mode of action of lead candidate molecules. Here the synthetic chemistry, the structure-guided design approach, and the structure-activity relationships (SARs) that led to the discovery of 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors, many with very low nM Kis against CDK2, are reported. Furthermore, X-ray crystal structures of four representative analogues from our chemical series in complex with CDK2 are presented, and these structures are used to rationalize the observed biochemical SARs. Finally results are reported that show, using the most potent CDK2 inhibitor compound from the current series, that the observed antiproliferative and proapoptotic effects are consistent with cellular CDK2 and CDK9 inhibition.

Anti-cancer compounds

The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.